⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EWTX News
Edgewise Therapeutics, Inc. Common Stock
Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026
prnewswire.com
EWTX
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors
prnewswire.com
EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
prnewswire.com
EWTX
Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers
prnewswire.com
EWTX
Edgewise Therapeutics to Participate in Upcoming Investor Conferences
prnewswire.com
EWTX
Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
prnewswire.com
EWTX